ESR1 and prostate carcinoma: Intriguingly, the designed two PROTACs demonstrated a great accuracy to AR and ER, as both Protac‐A and Protac‐B did not affect the proliferation of cells lacking ERα and AR.37 Tang et al later on demonstrated that the DHT‐PROTAC promoted AR degradation in LNCaP cells, confirmed the role of the PROTAC on ERα or AR positive cells.38 They investigated the degradation of AR for the effect on cell proliferation and viability for prostate cancer cells sensitive to androgen.